Description

3-Quinolinecarboxylic Acid, 8-Cyano-1-Cyclopropyl-6-Fluoro-7-[(4As,7As)-Hexahydropyrrolo[3,4-B]-1,4-Oxazin-6(2H)-Yl]-1,4-Dihydro-4-Oxo- is a high-purity, advanced pharmaceutical intermediate with a complex heterocyclic structure. This compound is of critical importance for its role as a key building block in the synthesis of novel antibacterial agents, particularly advanced-generation fluoroquinolone antibiotics. It is primarily required by research institutions and pharmaceutical manufacturers engaged in the development and production of new therapeutic drugs targeting resistant bacterial strains.

Application

• Pharmaceutical Intermediate: Serves as a crucial precursor in the synthesis of next-generation fluoroquinolone antibiotics.
• Antibacterial Drug Development: Used in R&D for creating new active pharmaceutical ingredients (APIs) with improved efficacy against drug-resistant bacteria.
• Chemical Synthesis Research: Employed in academic and industrial laboratories for studying structure-activity relationships (SAR) in medicinal chemistry.
• Process Chemistry: Utilized in scaling up and optimizing manufacturing routes for complex antibiotic molecules.
• Reference Standard: Can be supplied as a high-purity standard for analytical method development and quality control in API production.

Basic Information

Product Name	3-Quinolinecarboxylic Acid, 8-Cyano-1-Cyclopropyl-6-Fluoro-7-[(4As,7As)-Hexahydropyrrolo[3,4-B]-1,4-Oxazin-6(2H)-Yl]-1,4-Dihydro-4-Oxo-
CAS No.	209342-40-5
Molecular Formula	C20H19FN4O4
Molecular Weight	398.39 g/mol
Synonyms	8-Cyano-1-cyclopropyl-6-fluoro-7-[(4aS,7aS)-hexahydropyrrolo[3,4-b][1,4]oxazin-6(2H)-yl]-4-oxo-1,4-dihydroquinoline-3-carboxylic acid; Intermediate for Garenoxacin; Garenoxacin Intermediate; Garenoxacin Precursor; T-3811 Intermediate; (4aS,7aS)-7-(8-Cyano-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydroquinolin-3-yl)-5-oxo-2,3,4a,5,7,7a-hexahydropyrrolo[3,4-b][1,4]oxazine-6-carboxylic acid (tautomeric form)
EINECS	Contact for details

Quality Control

Our production of this advanced intermediate adheres to stringent quality management systems. Every batch undergoes comprehensive analytical testing, including HPLC for purity and impurity profiling, to ensure it meets the exacting standards required for pharmaceutical synthesis. Certificates of Analysis (COA) with full traceability are provided. We support development and commercial projects with material produced under GMP-like conditions where required, ensuring consistency and regulatory compliance.

Storage

Preserve in a tightly closed container, protected from light. Store in a cool, dry place at a controlled room temperature (15-25°C). This compound is hygroscopic (moisture-sensitive) and should be handled in a dry environment to prevent degradation. For long-term storage, consider desiccants or inert atmosphere packaging.

Specification

Item	Specification
Appearance	White to off-white crystalline powder
Identification (IR)	Conforms to reference spectrum
Identification (HPLC)	Retention time matches reference standard
Assay (HPLC)	≥ 98.0%
Related Substances (HPLC)	Total impurities ≤ 2.0% Any single impurity ≤ 0.5%
Water Content (KF)	≤ 1.0%
Residue on Ignition	≤ 0.1%

Note: Specifications can be tailored. Please contact us for the detailed technical data sheet of a specific grade.